Unreported negative trial results skew medical evidence, regulators seek more transparency

When unfavorable or inconclusive trial results stay buried, the public-health cost is immediate: doctors, patients and investors make decisions from a distorted evidence base. Federal rules already require many U.S. drug, biologic and device trials to register and post summary results on ClinicalTrials.gov, usually within 1 year of the primary completion date, but enforcement has remained the central question.

FDAAA 801 and the Final Rule, in effect since January 18, 2017, were written to make clinical testing more transparent. The U.S. Food and Drug Administration and the National Institutes of Health say those disclosures are meant to show both positive and negative findings, reduce bias and avoid waste. NIH policy likewise expects all NIH-funded clinical trials to register and submit results to ClinicalTrials.gov.

The pressure on regulators sharpened in January 2024, when the U.S. Department of Health and Human Services Office of Inspector General opened an audit of FDA oversight of results reporting. The audit focused on whether applicable clinical trial results were being reported to ClinicalTrials.gov within 1 year of completion, the standard laid out in the federal rule. That scrutiny reflects a long-running gap between the law on the books and what appears in the public registry.

FDA has enforcement tools it can use when sponsors miss deadlines. The agency says it can issue Pre-Notices for potential noncompliance, Notices of Noncompliance and civil money penalties. It said it had issued 77 Pre-Notice Letters and four Notices of Noncompliance after putting those processes in place. Even so, the persistence of missing data suggests the penalties have not yet forced broad compliance.

The transparency problem is not new. In 2024, The Lancet said results reporting in registries remained uncommon despite expanding legislative and funder requirements. In the same period, the Clinical Trials Transformation Initiative, working with FDA, said investigators and sponsors still faced barriers to timely, accurate and complete reporting and called for clearer guidance and training.

The stakes are large. FDA’s 2024 Drug Trials Snapshots covered the demographic makeup of trials behind 50 novel drugs approved in 2024 and found that about 31,000 patients participated in those studies. When negative results are left out, the record that informs prescribing, regulation and investment is incomplete, and the cost falls on the public first.